ArticleMolecular biology reports2026
Sirt3 deficiency impairs AMPK-Acc1 antilipogenic signaling in female adipocytes.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundBackground: Biological sex influences adipose tissue function, while impaired adipogenesis contributes to adipose dysfunction. Sirtuin 3 (Sirt3), a mitochondrial NAD+-dependent deacetylase involved in oxidative metabolism and stress adaptation, remains insufficiently defined in adipogenic differentiation. We investigated how Sirt3 and sex shape adipogenic phenotype in mouse embryonic fibroblast (MEF)-derived adipocytes. METHODS AND
resultsMale and female Sirt3 wild-type (WT) and knockout (KO) mouse MEFs were differentiated into adipocyte-like cells and analyzed by Oil Red O staining, confocal microscopy, lipid droplet morphometry, adipogenic gene expression, fatty acid profiling, LC-MS metabolomics, immunoblotting, and transmission electron microscopy (n = 3-5 biological replicates per group). All groups induced adipogenic marker expression and formed lipid rich adipocyte-like cells, with female KO adipocytes showing the strongest lipid storage phenotype. In females, bortezomib (BTZ) increased AMPK and Acc1 phosphorylation in WT adipocytes, whereas KO cells showed reduced basal pAMPK/AMPK and failed to mount a comparable AMPK-Acc1 response. AICAR failed to restore AMPK-Acc1 signaling in KO adipocytes. Sirt3 deficiency increased Scd1 abundance and the C16:1/C16:0 desaturation index. BTZ reduced Scd1 in KO cells without normalizing the elevated desaturation ratio. Metabolomics indicated predominantly BTZ-associated glycerophospholipid and lysophospholipid remodeling. Qualitative ultrastructural analysis revealed BTZ-associated organelle stress, most evident in KO adipocytes.
conclusionsSirt3 deficiency promotes a female biased lipid storage phenotype linked to impaired AMPK-Acc1 antilipogenic signaling, reduced lipid turnover, and persistent Scd1-associated fatty acid desaturation, supporting a model in which female adipocytes rely on Sirt3-dependent metabolic control during adipogenesis.
Indexed as
Identifiers
42886405What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.